Clovis

$4.44 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Clovis

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product Rubraca (rucaparib), an oral small molecule inhibitor of poly adenosine diphosphate (ADP)-ribose polymerase (PARP), is marketed in the United States for two indications specific to recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The Company also provides Lucitanib, which is an investigational, oral, potent inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors one through three (VEGFR1-3), platelet-derived growth factor receptors alpha and beta, and fibroblast growth factor receptors one through three (FGFR1-3).

Stock Analysis

last close $4.44
1-mo return 4.7%
3-mo return -25.5%
avg daily vol. 3.66M
52-week high 11.1
52-week low 4.06
market cap. $573M
forward pe -
annual div. -
roe -547.6%
ltg forecast -
dividend yield -
annual rev. $157M
inst own. 48.3%
baraka

Subscribe now for daily local and international financial news

Subscribe